natgillin/translations-raw huggingface dataset:
Cuprymina må udelukkende anvendes til radioaktiv mærkning af bæremolekyler, der er specielt beregnet til til radioaktiv mærkning med dette radioaktive lægemiddel.
This medicinal product must be used only for the radiolabelling of carrier molecules, which have been specifically developed for radiolabelling with this radionuclide.
Cuprymina, 925 MBq/ml, radiofarmaceutisk mærkningsopløsning
Cuprymina 925 MBq/mL radiopharmaceutical precursor, solution
Cuprymina, 925 MBq/ml, radiofarmaceutisk mærkningsopløsning
Cuprymina 925 MBq/mL radiopharmaceutical precursor, solution.
Cuprymina, 925 MBq/ml, radiofarmaceutisk mærkningsopløsning .
Cuprymina 925 MBq/mL radiopharmaceutical precursor, solution.
CURE-forsøget omfattede 12.562 patienter med akut koronarsyndrom uden forhøjelse af ST- segmentet (ustabil angina pectoris eller myokardieinfarkt uden forekomst af Q-takker), som indfandt sig inden for 24 timer efter starten på den seneste periode med brystsmerter eller symptomer der svarede til iskæmi.
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia.
CURE-undersøgelsen omfattede 12.562 patienter med akut koronarsyndrom uden forhøjelse af ST- segmentet (ustabil angina pectoris eller myokardieinfarkt uden forekomst af Q-takker), som indfandt sig inden for 24 timer efter starten på den seneste episode med brystsmerter eller symptomer, der svarede til iskæmi.
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia.
CURE-undersøgelsen omfattede 12.562 patienter med akut koronarsyndrom uden forhøjelse af ST- segmentet (ustabil angina pectoris eller myokardieinfarkt uden forekomst af Q-takker), som indfandt sig inden for 24 timer efter starten på den seneste periode med brystsmerter eller symptomer der svarede til iskæmi.
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia.
Curfew Bell Road Chertsey, Surrey KT16 9FG Storbritannien
Curfew Bell Road Chertsey, Surrey KT16 9FG United Kingdom
Curvularia spp. og Sporothrix spp.
Curvularia spp. and Sporothrix spp.
CuSCC var meget almindeligt rapporteret og blev sædvanligvis behandlet ved lokal eksicion.
CuSCC was very commonly reported and was most commonly treated by local excision.
Cushing-lignende symptomer, striae, ekkymoser, akne og hirsutisme, forringet sårheling.
Cushing-like symptoms, stria, ecchymoses, acne and hirsutism, impaired wound healing.
Cushingoide symptomer
Hallucination, amnesia
Cushingoide symptomer
Uncommon:
Cushings sygdom
Cushing’s disease
Cushings sygdom (en hormonsygdom, hvor kroppen producerer for meget af hormonet kortisol),
Cushing’s disease (a hormone disorder where the body produces too much of the hormone cortisol)
Cushings sygdom og akromegali skyldes begge svulster i hypofysen, der er en kirtel nederst i hjernen.
Cushing’s disease and acromegaly are both caused by tumours of the pituitary gland (a gland located at the base of the brain).
Cushings sygdom skyldes en forstørrelse af hypofysen (en kirtel på hjernens underside), som kaldes et hypofyseadenom.
Cushing’s disease is caused by an enlargement in the pituitary gland (a gland at the base of the brain) called a pituitary adenoma.
Cushings syndrom er en sygdom, der kendetegnes ved, at binyrerne producerer for meget kortisol.
Cushing’s syndrome is a disease characterised by an excess production of the hormone cortisol by the adrenal glands, two glands situated above the kidneys.
Cushings syndrom skyldes overproduktion af et hormon, der hedder kortisol og produceres i binyrerne.
Cushing’s syndrome is caused by overproduction of a hormone called cortisol which is produced by the adrenal glands.
Cushings syndrom*, hyperthyreoidisme*, uhensigtsmæssig produktion af antidiuretikahormon
Cushing's syndrome*, Hyperthyroidism*, Inappropriate antidiuretic hormone secretion
Cushings syndrom*, hypertyroidisme*, uhensigtsmæssig produktion af antidiuretikahormon
Cushing's syndrome*, Hyperthyroidism*, Inappropriate antidiuretic hormone secretion
Cushings syndrom, cushingoide træk, adrenal suppression, væksthæmning hos børn og unge, nedsat
Cushing’s syndrome, Cushingoid features, Adrenal suppression, Growth retardation in children and adolescents, Decreased bone mineral density
Cushings syndrom, cushingoide træk, adrenal suppression, væksthæmning hos børn og unge, nedsat knoglemineraltæthed
Cushing’s syndrome, Cushingoid features, Adrenal suppression, Growth retardation in children and adolescents, Decreased bone mineral density
Cushings syndrom, dvs. vægtøgning af kroppen og ansigtet, svedtendens, strækmærker, synlige opsvulmede små blodkar (kapillærer), hudtørhed, ekstra behåring i ansigtet (særlig hos kvinder) og tyndere hår
Cushing’s syndrome, i.e. weight gain of the trunk and face, excessive sweating, stretch marks, visible swollen capillaries (small blood vessels) and dryness of the skin, growth of extra facial hair (especially in women) and thinning of the hair;
Cut-off 1. februar 2012 (z)
February 01, 2012 data cut-off date (z)
Cut-off 30. december 2010 data (y)
December 30, 2010 data cut-off date (y)
Cut-off datoer
Cut-off dates
Cut-off point for den dynamiske test skal være nøjagtigt.
The cut-off point of the dynamic test should be strict.
CV = variationskoefficient Køn:
CV=coefficient of variation Gender:
CV d
No. at risk
CV død**
CV death
CV død, ikke-fatal MI 406 (13,4 %) 399 (13,2 %) 1,02 [0,89; 1,17]
CVdeath, non-fatal MI, 406 (13.4%) 399 (13.2%) 1.02 [0.89, 1.17]
CV) for adalimumab uden samtidig methotrexat og 10,9 ± 5,2 µg/ml (47,7% CV) med samtidig methotrexat.
± 5.6 µg/ml (102% CV) for adalimumab without concomitant methotrexate and 10.9 ± 5.2 µg/ml (47.7% CV) with concomitant methotrexate.
CV-død
CV Death
CV-dødsfald
CV death
CV-dødsfald/MI (tavst MI undtaget) eller apopleksi
CV death, MI (excl. silent MI) or stroke
CV-dødsfald/MI i alt/apopleksi/SRI/RI/ TIA eller andre ATEc
CV death, total MI, stroke, SRI, RI, TIA, or other ATEc
CV: intra-individuel variationskoefficient i % SS: steady state
CV: within-patient coefficient of variation in % SS: Steady State
CVA trad op bij 296 (7,8%) patiënten die clopidogrel + ASA kregen en bij 408 (10,8%) patiënten die placebo + ASA kregen (relatieve risicoreductie van 28,4%; 95% CI van 16,8% tot 38,3%; p=0,00001).
Strokes occurred in 296 (7.8%) patients receiving clopidogrel + ASA and 408 (10.8%) patients receiving placebo + ASA (relative risk reduction, 28.4%; 95% CI, 16.8% to 38.3%; p=0.00001).
CVMP anbefalede derfor udstedelse af markedsføringstilladelse for Improvac.
Therefore the CVMP recommended that Improvac should be given a marketing authorisation.
CVMP anså veterinærlægemidlet for at være effektivt til at eliminere loppeangreb og kontrollere og forebygge nye angreb af lopper og flåter i op til tre-fire uger efter behandlingen.
The CVMP considered that the medicine was effective in eliminating flea infestations and controling and preventing new flea and tick infestations for up to three to four weeks after treatment.
CVMP begrundelser for en yderligere fornyelse: Det Europæiske Lægemiddelagenturs debatoplæg vedr. kriterier for at kræve én yderligere fornyelse på fem år (EMEA/CVMP/430630/2006).
CVMP grounds for a further renewal: European Medicines Agency reflection paper on criteria for requiring one additional five year renewal (EMEA/CVMP/430630/2006).
CVMP blev ved deres møde den 8.-10. april 2014 enige om, at idet lægemidlet med den reviderede inaktiveringsproces kun har været markedsført i EU/EEA siden december 2012 samt at nye kvalitetsspecifikationer er blevet implementeret i 2013 for at forebygge alvorlige sikkerhedsproblemer set i besætninger, er en fuldstændig vurdering af konsekvensen af disse ændringer for øjeblikket ikke mulig.
The CVMP at their meeting on 8-10 April 2014 agreed that as the product with the revised inactivation process is only on the market in the EU/EEA since December 2012 and new quality specifications have been implemented in 2013 to prevent serious safety issues observed in the field, an assessment of the full impact of these changes is not possible at this moment.
CVMP fandt derfor, at fordelene ved Flexicam opvejer risiciene ved lindring af inflammation og smerter ved både akutte og kroniske lidelser i bevægeapparatet og ved begrænsning af postoperative smerter og inflammation efter ortopædiske operationer og bløddelskirurgi hos hunde og ved begrænsning af
The CVMP concluded that the benefits of Flexicam exceed the risks for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders, reduction of post- operative pain and inflammation following orthopaedic and soft tissue surgery in dogs and reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats and recommended that Flexicam be given a marketing authorisation.
CVMP konkluderede, at fordelene ved Bluevac BTV8 er større end risiciene ved aktiv immunisering af får og kvæg til forebyggelse af infektioner, viræmi og kliniske symptomer forårsaget af bluetonguevirus, serotype 8, og anbefalede udstedelse af markedsføringstilladelse for Bluevac BTV8.
The CVMP concluded that the benefits of Bluevac BTV8 outweigh the risks for the active immunisation of sheep and cattle to prevent infection, viraemia and clinical signs caused by bluetongue virus serotype 8, and recommended that Bluevac BTV8 be given a marketing authorisation.
CVMP konkluderede, at fordelene ved CaniLeish opvejer risiciene ved aktiv immunisering af leishmania- negative hunde fra seksmånedersalderen med henblik på at nedsætte risikoen for at udvikle aktiv infektion og klinisk sygdom efter kontakt med Leishmania infant, og anbefalede udstedelse af markedsføringstilladelse for CaniLeish.
The CVMP concluded that the benefits of CaniLeish outweigh the risks for the active immunisation of leishmania-negative dogs from six months of age to reduce the risk to develop an active infection and clinical disease after contact with Leishmania infantum and recommended that CaniLeish be given a marketing authorisation.
CVMP konkluderede, at fordelene ved Nexgard Spectra overstiger risiciene til de anbefalede anvendelser, og anbefalede udstedelse af markedsføringstilladelse for Nexgard Spectra.
The CVMP concluded that the benefits of Nexgard Spectra exceed the risks for the approved indications and recommended that Nexgard Spectra be given a marketing authorisation.
CVMP konkluderede, at fordelene ved ProZinc opvejer risiciene for den godkendte indikation, og anbefalede, at der udstedes markedsføringstiladelse for ProZinc.
The CVMP concluded that the benefits of ProZinc exceed the risks for the approved indication and recommended that ProZinc be given a marketing authorisation.
CVMP var derfor af den opfattelse, at fordelene ved Contacera - ligesom Metacam - er større end risiciene, når det anvendes til de godkendte indikationer, og udvalget anbefalede udstedelse af markedsføringstilladelse for Contacera.
Therefore the CVMP’s view was that, as for Metacam, Contacera’s benefits are greater than its risks when used for the approved indications and the Committee recommended that Contacera be given a marketing authorisation.
CVMP var derfor af den opfattelse, at fordelene ved Melovem ligesom Metacam er større end risiciene, når det anvendes til de godkendte indikationer, og udvalget anbefalede udstedelse af markedsføringstilladelse for Melovem.
Therefore, the CVMP’s view was that, as for Metacam, Melovem’s benefits are greater than its risks for the approved indications and the Committee recommended that Melovem be given a marketing authorisation.
CVMP var derfor af den opfattelse, at fordelene ved Meloxidolor ligesom ved Metacam er større end risiciene, når det anvendes til de godkendte indikationer, og anbefalede udstedelse af markedsføringstilladelse for Meloxidolor.
Therefore the CVMP’s view was that, as for Metacam, Meloxidolor’s benefits are greater than its risks when used for the approved indications and the Committee recommended that Meloxidolor be given a marketing authorisation.
CVMP var derfor af den opfattelse, at fordelene ved Meloxidyl, ligesom Metacam, opvejer risiciene.
Therefore the CVMP’s view was that, as for Metacam, Meloxidyl’s benefits are greater than its risks.
CVMP var derfor af den opfattelse, at fordelene ved RevitaCAM ligesom Metacam er større end risiciene, når det anvendes til de godkendte indikationer, og udvalget anbefalede udstedelse af markedsføringstilladelse for RevitaCAM.
Therefore the CVMP’s view was that, as for Metacam, RevitaCAM’s benefits are greater than its risks when used for the approved indications and the
CVMP var derfor af den opfattelse, at fordelene ved Rheumocam, som ved Metacam, er større end risiciene, når det anvendes til de godkendte indikationer, og anbefalede udstedelse af en markedsføringstilladelse for Rheumocam.
Therefore the CVMP’s view was that, as for Metacam, Rheumocam’s benefits are greater than its risks when used for the approved indications and the Committee recommended that Rheumocam be given a marketing authorisation.
CVMP var derfor af den opfattelse, at Meloxivet ligesom Metacam 1,5 mg/ml oral suspension opvejer risiciene ved behandling af smerter i muskler eller led hos hunde og anbefalede udstedelse af markedsføringstilladelse for Meloxivet.
Therefore the CVMP’s view was that, as for Metacam 1.5 mg/ml oral suspension, Meloxivet’s benefits are greater than its risks when treating inflammation or pain in muscles or joints in dogs and they recommended that Meloxivet should be given a marketing authorisation.
CVMP vurderede, at det i overensstemmelse med EU-kravene er blevet påvist, at Loxicom er bioækvivalent med Metacam.
The CVMP considered that, in accordance with European Union requirements, Loxicom has been shown to be bioequivalent to Metacam.
CVMP vurderede, at det i overensstemmelse med EU-kravene er blevet påvist, at Rheumocam er bioækvivalent med Metacam.
The CVMP considered that, in accordance with European Union requirements, Rheumocam has been shown to be bioequivalent to Metacam.
CVMP-konklusioner for yderligere fornyelse
CVMP grounds for a further renewal:
CVVH ≤ 30 ml/min 250 mg hver 12. time 4 timer ≤ 1 mg/l
CVVH ≤ 30 ml/min 250 mg every 12 hours 4 hours ≤ 1 mg/l
CVVHDF < 5 ml/min 250 mg hver 12. time 4 timer ≤ 1 mg/l
CVVHDF < 5 ml/min 250 mg every 12 hours 4 hours ≤ 1 mg/l
Cyanidforgiftede patienter
Cyanide-poisoned patients
Cyanokit
administration
Cyanokit 2,5 g pulver til infusionsvæske, opløsning Hydroxocobalamin
Cyanokit 2.5 g powder for solution for infusion Hydroxocobalamin
Cyanokit kan påvirke vurderingen, da det forårsager en rødfarvning af huden. hæmodialyse.
Cyanokit may interfere with the assessment as it causes red coloration of the skin. haemodialysis.
Cyanokit kan ændre resultaterne af disse prøver. brandsårsvurdering.
Cyanokit may modify the results of these tests. burn assessement.
Cyanokit kan, til ambulant brug, i korte perioder udsættes for temperaturudsving under almindelig transport (15 dage med temperaturer mellem 5 °C og 40 °C) transport i ørkenen (4 dage med temperaturer mellem 5 °C og 60 °C) og nedfrysnings-/optøningscyklusser (15 dage med temperaturer mellem -20 °C og 40 °C)
For the purpose of ambulatory use, Cyanokit may be exposed during short periods to the temperature variations of usual transport (15 days submitted to temperatures ranging from 5 to 40°C) transport in the desert (4 days submitted to temperatures ranging from 5 to 60°C) and freezing/defrosting cycles (15 days submitted to temperatures ranging from -20 to 40°C).
Cyanose
Flushing
cyclo-, tro- og iphosphamider sulfinpyrazon visse langtidsvirkende sulfonamider tetracykliner
cyclo-, tro-and iphosphamides sulphinpyrazone certain long-acting sulphonamides tetracyclines
Cyclobenzapr
GIVEN WITH
cyclobenzaprin, carisoprodol
cyclobenzaprine, carisoprodol
Cyclooxygenase- enzymet (COX) findes i to former.
The cyclooxygenase enzyme (COX) is present in two forms.
Cyclophosphamid (n  98)
Cyclophosphamide (n  98)
cyclophosphamid, der bruges til behandling af kræft
cyclophosphamide, used for cancer,
cyclophosphamid, ifosfamid, trofosfamid (til behandling af kræft)
cyclophosphamide, ifosfamide, trofosfamide (to treat cancer)
Cyclophosphamid, melphalan eller fludarabin anvendes til at dæmpe immunsystemet, så kroppens naturlige forsvar nedsættes.
Cyclophosphamide, melphalan or fludarabine are used to suppress the immune system, so that the body’s natural defences are decreased.
Cyclosporin, sirolimus (rapamycin), tacrolimus: Koncentrationerne kan være øget på grund af Kaletras hæmning af CYP3A.
Cyclosporin, Sirolimus (rapamycin), Tacrolimus: Concentrations may be increased due to CYP3A inhibition by Kaletra.
Cyclus 2-4b
Cycles 2 to 4b
Cycon Chemicals Ltd 5 Promitheos Str 1065
VTN Veterinary and Pharmacy Ltd.
Cyklus 1, dosis 2
Cycle 1, Dose 2
Cyklus 13 og fremefter
Cycles 13 on
Cyklus 2 - 4b
Cycles 2 to 4b
Cyklus 2 og efterfølgende cyklusser (dag 1 - 28)
Cycle 2 and subsequent cycles (Days 1 - 28)
Cyklus 2 til 4b
Cycles 2 to 4b
Cyklus 2-12
Cycles 2-12
Cyklus 2-4b
Cycles 2 to 4b
Cyklus- dag
Cycle Day
Cyklusdag
Day of Cycle
Cyklusser i PURSUE‡ med oplægning af friske embryoner
Fresh Cycles of PURSUE
Cyklusserne blev gentaget hver 3. uge i 3 cyklusser.
The cycles were repeated every 3 weeks for 3 cycles.
Cylinder
e e
Cylinder
Needle
Cylinder
Pen barrel
Cylinder
Syringe body
Cylinder (aluminium)
gas cylinder (aluminium)
Cylinder- ampul
Cartridge
Cylinderampu l (glas)
Cartridge (glass)
Cylinderampu l (glas) i fyldt pen
Cartridge (glass) in pre- filled pen
Cylinderampul
Cartridge
Cylinderampul
cartridge (glass)
Cylinderampul
cartridge (glass) cartridge (glass)
Cylinderampul
in disposable pen cartridge (glass)
cylinderampul (DCC - Dual Chamber Cartridge) i fyldt pen
Dual Chamber Cartridge (DCC) in pre-filled pen
Cylinderampul (glas
cartridge (glass)
cylinderampul (glas)
cartridge (glass)
Cylinderampul (glas)
cartridge (glass) in
cylinderampul (glas)
cartridges (glass)
Cylinderampul (glas) (Penfill)
cartridge (glass) (Penfill)
Cylinderampul (glas) for
cartridge (glass) for
cylinderampul (glas) i
Cartridge (glass) in
cylinderampul (glas) i
Vial (glass)
cylinderampul (glas) i en forfyldt pen (SoloStar)
cartridge (glass) in pre-filled pen (SoloStar)
cylinderampul (glas) i en fyldt pen
cartridge (glass) in a pre-filled pen
cylinderampul (glas) i engangspen (SoloStar)
cartridge (glass) in pre-filled pen (SoloStar)
cylinderampul (glas) i flerdosispen
Cartridge (glass) in
cylinderampul (glas) i flerdosispen
Vial (glass)
cylinderampul (glas) i forfyldt pen (OptiSet)
cartridge (glass) in pre-filled pen (OptiSet)
cylinderampul (glas) i forfyldt pen (SoloStar)
cartridge (glass) in pre-filled pen (SoloStar)
Cylinderampul (glas) i fyldt pen
Cartridge (glass) in pre- filled pen
Cylinderampul (glas) i fyldt pen
Cartridge (glass) in pre-filled pen
Cylinderampul (glas) i fyldt pen (FlexPen)
cartridge (glass) in pre-filled pen (FlexPen)
Cylinderampul (glas) i fyldt pen (FlexPen) med nåle
cartridge (glass) in pre-filled pen (FlexPen) with needles
Cylinderampul (glas) i fyldt pen (FlexTouch)
cartridge (glass) in pre-filled pen (FlexTouch)
Cylinderampul (glas) i fyldt pen (FlexTouch) med nåle
cartridge (glass) in pre-filled pen (FlexTouch) with needles
Cylinderampul (glas) i fyldt pen (InnoLet)
cartridge (glass) in pre-filled pen (InnoLet)
Cylinderampul (glas) i fyldt pen (SoloStar)
(glass) in pre-filled pen (SoloStar)
Cylinderampul (glas) i fyldt pen (SoloStar)
(glass) in pre-filled pen (SoloStar) cartridge
Cylinderampul (glas) i fyldt pen (SoloStar)
cartridge (glass) in pre-filled pen (SoloStar) cartridge
cylinderampul (glas) til OptiClik
cartridge (glass) for OptiClik
Cylinderampul (type 1 glas) med et stempel (brombutyl) og en gummiprop (brombutyl/polyisopren), indeholdende 3 ml injektionsvæske i en fyldt engangspen til flergangsbrug lavet af polypropylen.
Cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene) containing 3 ml of suspension in a pre-filled multidose disposable pen made of polypropylene.
Cylinderampul (type 1 glas) med et stempel (brombutyl) og en gummiprop (brombutyl/polyisopren), indeholdende 3 ml injektionsvæske i en fyldt engangspen til flergangsbrug lavet af polypropylene.
Cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene) containing 3 ml of suspension in a pre-filled multidose disposable pen made of polypropylene.
Cylinderampul (type 1 glas) med et stempel (brombutyl) og en gummiprop (brombutyl/polyisopren), indeholdende 3 ml injektionsvæske.
Cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene) containing 3 ml of suspension.
Cylinderampul (type 1-glas) med et stempel (brombutyl) og en gummiprop (brombutyl/polyisopren) i en fyldt flerdosis engangspen af polypropylen, indeholdende 3 ml injektionsvæske.
Cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene) containing 3 ml of suspension in a pre-filled multidose disposable pen made of polypropylene.
Cylinderampul (type 1-glas) med et stempel (brombutyl) og en gummiprop (brombutyl/polyisopren), indeholdende 3 ml injektionsvæske i en fyldt flerdosis engangspen af polypropylen.
Cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene) containing 3 ml of suspension in a pre-filled multidose disposable pen made of polypropylene.
Cylinderampul (type 1-glas) med et stempel (brombutyl) og en gummiprop (brombutyl/polyisopren), indeholdende 3 ml injektionsvæske.
Cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene) containing 3 ml of suspension.
Cylinderampul (type 1-glas) med et stempel (brombutyl) og et gummiprop (brombutyl/polyisopren), indeholdende 3 ml injektionsvæske.
Cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene) containing 3 ml of suspension.
Cylinderampul (type 1-glas) med stempel (brombutyl) og en prop (brombutyl/polyisopren) i en fyldt engangspen til flergangsbrug (polyolefin og polyacetal).
Cartridge (type 1 glass) with a plunger (bromobutyl) and a stopper (bromobutyl/polyisoprene) contained in a pre­filled multidose disposable pen made of polyolefin and polyacetal.
Cylinderampul (type I glas), med et gummistempel (brombutylgummi) og et beskyttelseslåg (aluminium) med et septum (brombutylgummi), som indeholder 0,75 ml opløsning.
Cartridge (type I glass) with a rubber piston (bromobutyl rubber) and a crimp-cap (aluminium) with a septum (bromobutyl rubber), containing 0.75 mL of solution..
Cylinderampul (type I glas), med et gummistempel (brombutylgummi) og et beskyttelseslåg (aluminium) med et septum (brombutylgummi), som indeholder 1,5 ml opløsning.
Cartridge (type I glass) with a rubber piston (bromobutyl rubber) and a crimp-cap (aluminium) with a septum (bromobutyl rubber), containing 1.5 mL of solution..
Cylinderampul af type I glas med et (brombutyl) gummistempel, beskyttelseshætte (aluminium) med indsatte laminerede tætningsskiver (brombutylgummi på produktsiden og polyisopren på ydersiden).
Type I glass cartridge with a (bromobutyl) rubber plunger, flanged caps (aluminium) with inserted laminated sealing disks (bromobutyl rubber on the product side and polyisoprene on the outside).
Cylinderampul i fyldt pen
cartridge (glass) in pre-filled pen
Cylinderampul i fyldt pen
cartridge in pre- filled pen
cylinderampul i fyldt pen (250 mikrogram/
Cartridge in a pre- filled pen (250 micrograms/
CYLINDERAMPUL TIL OPTICLIK, ETIKET
CARTRIDGE FOR OPTICLIK LABEL
CYLINDERAMPUL TIL OPTICLIK, ETIKET
CARTRIGE FOR OPTICLIK LABEL
Cylinderampul til OptiClik:
Cartridge for OptiClik: